Pathogenic relationship between myeloproliferative neoplasms and lymphohematopoietic neoplasms

Author: Yi-an ZHANG ¹ ; Peng LIU ¹
Author Information

1. Department of Hematology, Zhongshan Hospital, Fudan University Shanghai, 200032, China
Publication Type:Journal Article
Keywords: myeloproliferative neoplasm; lymphoma; myelofibrosis; JAK inhibitors; Ruxolitinib
From: Chinese Journal of Practical Internal Medicine 2019;39(02):135-138
CountryChina
Language:Chinese
Abstract: The pathogenic relationship between myeloproliferative neoplasms(MPN) and lymphoid neoplasms has not been completely elucidated. With the progression of MPN treatment, the patients' survival has been prolonged owing to the use of JAK inhibitors(ruxolitinib). However, the side effects of JAK inhibitors also exist. In order to understand the natural course of this chronic disease accompanied with other hematological diseases and the characteristics and prognosis of secondary MPN, we conducted a literature review.